🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. ASCs (Cx401, company code)

    Takeda

    Anal Fistula

    phase 3 small molecule completed

    1 trial

  2. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

  4. ASPRO 320 mg, comprimé, CALCIUM HYDROGEN PHOSPHATE DIHYDRATE, DICLOFENAC ARROW 1 %, gel en flacon pressurisé

    Tour Hekla

    Thrombotic episodes in superficial venous malformations in children

    phase 3 small molecule active

    1 trial

  5. ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 other active

    1 trial

  6. ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión

    Lacuna Pharma Pty Ltd

    Congenital antithrombin deficiency

    phase 3 small molecule active

    1 trial

  7. ATLG

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematopoietic Stem Cell Transplantation

    phase 3 small molecule active

    1 trial

  8. ATOMOXETINE , PAROXETINE , MIANSERIN , VORTIOXETINE , VENLAFAXINE , DESVENLAFAXINE , KETAMINE , CLOMIPRAMINE , DULOXETINE , DOSULEPIN , IMIPRAMINE , AMITRIPTYLINE , ESCITALOPRAM , NORTRIPTYLINE , MILNACIPRAN , SERTRALINE , ESKETAMINE , FLUVOXAMINE , REBOXETINE , FLUOXETINE , TRAZODONE , CITALOPRAM , BUPROPION , AGOMELATINE , MIRTAZAPINE , ESKETAMINE , TIANEPTINE

    Disc Medicine

    Major depressive disorder

    phase 3 small molecule active

    1 trial

  9. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  10. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  11. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  12. AVP-786 matching Placebo, AVP-786, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  13. AVP-786 matching placebo, AVP-786

    Otsuka Beijing Research Institute

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule active

    1 trial

  14. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  15. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial

  16. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  17. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  18. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  19. AZACITIDINE, Venetoclax, Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  20. AZATHIOPRINE, METHYLPREDNISOLONE, PREDNISONE, AZATHIOPRINE, PREDNISOLONE, RITUXIMAB

    Pari Pharma GmbH

    myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)

    phase 3 small molecule active

    1 trial

  21. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. AZD0780, AZD0780 Placebo

    AstraZeneca AB

    Hyperlipidemia, Atherosclerotic cardiovascular disease

    phase 3 small molecule active

    1 trial

  23. AZD7270, AZD7270, Lokelma 5 g powder for oral suspension, AZD7270, Lokelma 5 g powder for oral suspension

    AstraZeneca AB

    Hyperkalaemia

    phase 3 small molecule active

    1 trial

  24. Abicipar Pegol

    Allergan Pharmaceuticals International Limited

    Macular Degeneration

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources